Objective To determine an appropriate duration for a short course of oral steroids in cases of asthmaexacerbations.
Introduction
The introduction of inhaled corticosteroids (ICS) has led to a drastic change in the treatment of asthma in Japan (1) . However, asthma can manifest itself in a variety of conditions which may not be completely manageable by ICS alone. Given this situation, it is crucial to use appropriate combinedtreatment modalities. Amongthese, a short rescue course of oral steroids is one of the most important strategies which maybe needed at any step and at any time (2) (3) (4) . Although it is obvious that this strategy has an essential role to play in the long term management of asthma, it is not entirely clear just how long such a course should be continued. Wepreviously reported the results of a retrospective comparison between a 3-day and a 2-week course of oral prednisolone for acute exacerbations of asthma (5), the results of which prompted us to examine the duration between these two courses. Wetherefore compared the effectiveness of a 1-week and a 2-week course of oral prednisolone (PSL) following a 3-day course of intravenous methyl-prednisolone (m-PSL) in 20 asthmapatients whowereadmitted to our hospital due to acute exacerbations.
Patients and Methods
Asthmatics whowere admitted to our hospital due to acute exacerbation were eligible except in a case of 1) near fatal attacks, 2) serious complicated diseases, 3) pregnancy. All patients were initially treated with intravenous m-PSL(80 mg, every 8 hours) for a 3-day period after admission. They were then randomly allocated into 2 groups. Patients in one group were administered 0.5 mg/kg of PSL for a period of 1 week (1 W), while patients in the other group were treated with the same dose of PSL for a 2-week period (2 W). After completing the oral steroids, all patients were treated with beclomethasone dipropionate (BDP). Patients who had been using BDPbefore their admission restarted BDPat the samedose as before their admission. For those who had never had BDPbefore their admission, the dose was 800 |ig/day. The primary outcome measure was the morning PEF which had been self-monitored by Mini-Wright peak flow meter. The change over the course of time during a 4-week period after the initiation of oral steroids was compared by the 2-way Duration of Systemic Steroids in Asthma ANOVA. A secondary outcome measure was unscheduled hospital visits due to asthma exacerbation during the 6-month period after discharge. They were evaluated by %2test. Unpaired t test was also used to comparebaseline factors of the patients in each group when indicated.
Results
Twentyevaluable patients were enrolled in the study. Ten were randomly allocated to 1 W, and 10 to 2 W. Characteristics of the study subjects are shown in Table 1 . Only 4 patients had been using inhaled steroids regularly (daily dose of 200, 500, 900 and 1,600 meg, respectively). Because we did not have a PEFbased strict admission criteria at the time of the study, there were considerable variations in the severity of both asthma itself and its exacerbation. However, no significant difference was seen between the 2 groups in any factors, including type and severity of asthma, although patients in 1 Wtended to have had their asthma for a longer period of time. Figure 1 shows changes in PEFover the course of time. MeanPEFsjust before starting oral PSL in 1 Wand 2 Wwere 51 and 58%of each patient's best value, respectively. These each increased to 68%on day 7. Further improvement to 71 and 73%were seen on day 14. Both changes were statistically significant, and there was no difference between the 2 groups. Furthermore, although improvement during the first week of the treatment (days 1-7) was significant, the changes after day 8 were not significant in either 1 Wand 2 W. Steroid-induced best PEF, which was defined as the patient's best PEF during the 4-week period after the initiation of oral PSL treatment, was compared with long-term personal best PEF, which was defined as their best PEF over a period of 6 months after discharge ( Table 2) . The percentage of patients in whom personal best PEF was induced by the course of oral PSL was similar in 1 Wand 2 W. Amongpatients whose personal best was different from their steroid-induced best, the difference between these 2 PEF values tended to be larger in 1 W. However, such differences were generally small and insignificant (15 vs. 4.4%, p=0.08).
Finally, 4 patients (2 in 1 W and 2 in 2 W) needed unscheduled hospital visits during the 3-month period after discharge. Neither of the patients in 1 Wor 2 Wwere readmitted during the sameperiod. Number (%) of subjects who reached personal 5 6 1 1 best PEF within a 4-week period after (50%) (60%) (55%) the course of oral steroids Difference between steroid-induced best* 1 5±4.3 4.4± 1.6 1 0±3.0 and personal best * PEF (7-3 1) (2-9) (2-3 1) mean±SE (range) % *: The best PEF within a 4-week period after the course of oral steroids. *: The best PEF within a 6-month period after discharge.
Guidelines for asthma managementindicate that patients with asthma mayneed a short course of oral steroids to control their exacerbation at any time and at any step (2-A). Although there is no consensus regarding doses of systemic steroids (6), relatively high doses are recommended in all guidelines because a dose-response relationship for systemic steroids has been documented (7). There is a very little information, however, in terms of the duration of such a course.
In fact, guidelines differ considerably with regard to duration. British guidelines on asthma managementrecommendthat a short course of oral steroids should be continued until exacerbation is completely controlled (3) , and that a duration of up to 3 weeks may be safe. Global Initiative for Asthma defines a 5 to 7 day course as the maximumtherapy (4). There was also a report which described the usefulness of an 8-day course of oral steroids in reducing early relapse of asthma exacerbation among patients who had visited an emergency room (8) . Two weeks has been considered the standard duration as the term "steroid resistant asthma" has been defined as a patient who does not respond to a 2-week course of systemic steroids. Exacerbation of asthma differs according to cause and severity. It could be stated, therefore, that the dose and duration of the course should be adjusted accordingly. However, a short course of oral steroids should be administered as soon as possible after exacerbation occurs, as treatment failure tends to happen in the early phase of the treatment (9) . Ideally, the course should therefore be administered on a self-management basis. For this reason, the physician should give an appropriate amount of oral steroids to patients in advance, and give them instruction regarding the specific dose and duration of the course, which should be simple and easy to understand.
In the present study, both the 1-week and the 2-week course of oral PSLfollowing a 3-day course of intravenous steroids Duration of Systemic Steroids in Asthma had a similar impact on the improvement of PEF in asthma exacerbations resulting in hospital admission. The frequency of unscheduled hospital visits due to early relapse was also similar in both groups. Furthermore, the changes in PEF after day 8 were not significant in either 1 Wor 2 W. These observations indicate that the effect of systemic steroids appears rapidly and reaches a plateau within a period of less than 2 weeks. One may argue that patients with exacerbation should be treated more intensively, as patients' PEF reached a plateau at around 70%of their best value in the present study. However, because the changes in PEFover the course of time were very similar in 1 Wand 2 W, and also because the changes in PEF after day 8 were not significant in both groups, we do not think that the longer period of oral steroids would make a big difference. In addition, strict adherence to PEFcut-off value using the patient's best value irrespective of time of day or prior use of bronchodilator would lead to considerable overtreatment in asthmatics who had been taking inhaled corticosteroids ( 10) , and might consequently increase the risk / benefit ratio in asthma treatment.
Because the course of oral PSL began following a 3-day course of intravenous m-PSLin both 1 Wand 2 W, a comparison was actually performed between 10 and 17 days of systemic steroids. However, this study was conducted in patients whoneeded hospital admission. The exacerbations were generally more severe than those experienced by the outpatients in our previous comparison (5) . In fact, PEF just before starting oral steroids in the present study was similar to that in the previous one. Thus, although it is possible that the effect of the oral steroids was boosted by that of preceding m-PSL, the results of the present study may give some insight regarding the duration of oral steroids in asthma exacerbation amongoutpatients.
In conclusion, we suggest that a course of systemic steroids lasting more than 10 days may have little benefit in the treatment of asthma exacerbation. Onan outpatient basis, 1 week, rather than 2 weeks, maybe appropriate as the maximumduration for a short rescue course of oral steroids. Furthermore, because patients have a similar chance of reaching their best PEF during a period of4 weeks in both a 1-week and a 2-week course, 2 weeks may not be necessary to induce personal best PEF in the initial treatment of asthma.
